Georges M, Perez T, Rabec C, Jacquin L, Finet-Monnier A, Ramos C, Patout M, Attali V, Amador M, Gonzalez-Bermejo J, Salachas F, Morelot-Panzini C
Service des maladies respiratoires et des soins intensifs, centre de référence pour les maladies pulmonaires rares de l'adulte, hôpital universitaire de Dijon-Bourgogne, Dijon, France; Université de Bourgogne-Franche-Comté, Dijon, France; Centre des sciences du goût et de l'alimentation, UMR 6265, CNRS 1234, INRA, université de Bourgogne-Franche-Comté, Dijon, France.
Service des maladies respiratoires, hôpital universitaire de Lille, Lille, France; Centre d'infection et d'immunité de Lille, Inserm U1019-UMR9017, université de Lille-Nord de France, Lille, France.
Rev Mal Respir. 2024 Oct;41(8):620-637. doi: 10.1016/j.rmr.2024.06.006. Epub 2024 Jul 16.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive diaphragm weakness and deteriorating lung function. Bulbar involvement and cough weakness contribute to respiratory morbidity and mortality. ALS-related respiratory failure significantly affects quality of life and is the leading cause of death. Non-invasive ventilation (NIV), which is the main recognized treatment for alleviating the symptoms of respiratory failure, prolongs survival and improves quality of life. However, the optimal timing for the initiation of NIV is still a matter of debate. NIV is a complex intervention. Multiple factors influence the efficacy of NIV and patient adherence. The aim of this work was to develop practical evidence-based advices to standardize the respiratory care of ALS patients in French tertiary care centres.
For each proposal, a French expert panel systematically searched an indexed bibliography and prepared a written literature review that was then shared and discussed. A combined draft was prepared by the chairman for further discussion. All of the proposals were unanimously approved by the expert panel.
The French expert panel updated the criteria for initiating NIV in ALS patients. The most recent criteria were established in 2005. Practical advice for NIV initiation were included and the value of each tool available for NIV monitoring was reviewed. A strategy to optimize NIV parameters was suggested. Revisions were also suggested for the use of mechanically assisted cough devices in ALS patients.
Our French expert panel proposes an evidence-based review to update the respiratory care recommendations for ALS patients in daily practice.
肌萎缩侧索硬化症(ALS)是一种神经退行性疾病,其特征为膈肌进行性无力和肺功能恶化。延髓受累和咳嗽无力会导致呼吸疾病和死亡。ALS相关的呼吸衰竭会显著影响生活质量,并且是主要死因。无创通气(NIV)是缓解呼吸衰竭症状的主要公认治疗方法,可延长生存期并改善生活质量。然而,开始使用NIV的最佳时机仍存在争议。NIV是一种复杂的干预措施。多种因素会影响NIV的疗效和患者的依从性。这项工作的目的是制定基于实际证据的建议,以规范法国三级护理中心ALS患者的呼吸护理。
对于每项提议,法国专家小组系统地检索了索引文献目录并撰写了书面文献综述,然后进行分享和讨论。主席编写了一份综合草案以供进一步讨论。所有提议均得到专家小组的一致批准。
法国专家小组更新了ALS患者开始使用NIV的标准。最新标准于2005年制定。纳入了开始使用NIV的实用建议,并对可用于NIV监测的每种工具的价值进行了评估。提出了优化NIV参数的策略。还建议对ALS患者使用机械辅助咳嗽装置进行修订。
我们的法国专家小组提出了一项基于证据的综述,以更新日常实践中ALS患者的呼吸护理建议。